Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 464 Melanoma 300 Squamous Cell Carcinoma of Head and Neck 234 Parkinson Disease 4, Autosomal Dominant Lewy Body 189 Neoplasms 185 Triple Negative Breast Neoplasms 163 Breast Neoplasms 162 Neoplasm Metastasis 157 Lung Neoplasms 147 Colorectal Neoplasms 142 Carcinoma, Renal Cell 132 Head and Neck Neoplasms 123 Stomach Neoplasms 104 Ovarian Neoplasms 101 Carcinoma, Transitional Cell 91 Urinary Bladder Neoplasms 81 Pancreatic Neoplasms 81 Endometrial Neoplasms 74 Carcinoma, Hepatocellular 74 Uterine Cervical Neoplasms 63 Esophageal Neoplasms 57 Recurrence 52 Prostatic Neoplasms 49 Sarcoma 43 Carcinoma 42 Glioblastoma 40 Small Cell Lung Carcinoma 39 Carcinoma, Squamous Cell 39 Hodgkin Disease 36 Cholangiocarcinoma 35

Interventions

valrubicin 3 dodecyl maltoside 3 Mitomycin 3 Magnetic Resonance Imaging 3 Gemcitabine 3 durvalumab 2 Interferon beta-1b 2 Electrocardiography 2 Diphenhydramine 2 Cystoscopy 2 Biopsy 2 Acetaminophen 2 toripalimab 1 pembrolizumab 1 fludarabine phosphate 1 fludarabine 1 enfortumab vedotin 1 cemiplimab 1 apaziquone 1 aldesleukin 1 advexin 1 Tomography, X-Ray Computed 1 Surveys and Questionnaires 1 Standard of Care 1 Sampling Studies 1 Respiratory Function Tests 1 Proflavine 1 Prochlorperazine 1 Positron-Emission Tomography 1 Physical Examination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma in Situ × pembrolizumab × Clear all

NCT04387461 2024-09-25

CORE-001

CG Oncology, Inc.

Phase 2 Completed

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon ⚡